These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16554542)

  • 1. Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C.
    van der Eijk AA; Vrolijk JM; Haagmans BL
    N Engl J Med; 2006 Mar; 354(12):1323-4. PubMed ID: 16554542
    [No Abstract]   [Full Text] [Related]  

  • 2. Weight-based versus fixed dosing of peginterferon (40kDa) alfa-2a.
    Lamb MW; Martin NE
    Ann Pharmacother; 2002 May; 36(5):933-5. PubMed ID: 12014351
    [No Abstract]   [Full Text] [Related]  

  • 3. [Successful therapy with pegylated interferon alfa-2a. Hepatitis C patients remain virus-free].
    MMW Fortschr Med; 2003 Sep; 145(35-36):56. PubMed ID: 14584218
    [No Abstract]   [Full Text] [Related]  

  • 4. Pegylated interferons.
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(2):87-99. PubMed ID: 12120178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).
    Silva M; Poo J; Wagner F; Jackson M; Cutler D; Grace M; Bordens R; Cullen C; Harvey J; Laughlin M
    J Hepatol; 2006 Aug; 45(2):204-13. PubMed ID: 16780997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peginterferons in hepatitis C virus: virological, pharmacokinetic, and clinical implications. Introduction.
    Keeffe EB
    Semin Liver Dis; 2003; 23 Suppl 1():1-2. PubMed ID: 12934161
    [No Abstract]   [Full Text] [Related]  

  • 7. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.
    Forestier N; Reesink HW; Weegink CJ; McNair L; Kieffer TL; Chu HM; Purdy S; Jansen PL; Zeuzem S
    Hepatology; 2007 Sep; 46(3):640-8. PubMed ID: 17879366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.
    Fried MW; Hadziyannis SJ
    Semin Liver Dis; 2004; 24 Suppl 2():47-54. PubMed ID: 15346246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing antibodies to interferon alpha in a chronic hepatitis C patient non-responder to pegylated interferon.
    Santantonio T; Milella M; Antonelli G; Scagnolari C
    J Hepatol; 2006 Nov; 45(5):759-61. PubMed ID: 16979777
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiviral effect of peginterferon alfa-2b and alfa-2a compared.
    Jansen PL; Reesink HW
    J Hepatol; 2006 Aug; 45(2):172-3. PubMed ID: 16797101
    [No Abstract]   [Full Text] [Related]  

  • 11. Proceed with caution: peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C. A systematic review of randomized trials.
    Kershenobich D; Muñoz L; Malé R; Gaytan J; Sánchez F
    Hepatology; 2010 Dec; 52(6):2240-1; author reply 2241-2. PubMed ID: 21105116
    [No Abstract]   [Full Text] [Related]  

  • 12. Pegylation of interferon alfa: structural and pharmacokinetic properties.
    Pedder SC
    Semin Liver Dis; 2003; 23 Suppl 1():19-22. PubMed ID: 12934164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained remission of chronic hepatitis C after a change to human leukocyte interferon-alpha in a difficult-to-treat patient with breakthrough phenomenon associated with antibodies against recombinant interferon-alpha.
    Berg T; Hopf U; Schuff-Werner P
    Am J Gastroenterol; 2001 Feb; 96(2):612-4. PubMed ID: 11232730
    [No Abstract]   [Full Text] [Related]  

  • 14. [A 72 week follow-up study of chronic hepatitis C patients treated with peginterferon alfa-2b and ribavirin].
    Yu SL; Zhang ZH; Lv H; Zhang QG; Wang YZ
    Zhonghua Gan Zang Bing Za Zhi; 2007 Mar; 15(3):231. PubMed ID: 17407724
    [No Abstract]   [Full Text] [Related]  

  • 15. Peginterferon alfa-2a in patients with chronic hepatitis C.
    Zeuzem S; Feinman SV; Rasenack J; Heathcote EJ; Lai MY; Gane E; O'Grady J; Reichen J; Diago M; Lin A; Hoffman J; Brunda MJ
    N Engl J Med; 2000 Dec; 343(23):1666-72. PubMed ID: 11106715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of chronic hepatitis C with peginterferon alpha-2a and the factors influencing the effect of this treatment].
    Jin GD; Gong QM; Mao HJ; Xu DZ; Lu ZM
    Zhonghua Gan Zang Bing Za Zhi; 2005 Apr; 13(4):302-4. PubMed ID: 15850524
    [No Abstract]   [Full Text] [Related]  

  • 17. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C.
    Rakov NE
    N Engl J Med; 2003 Jan; 348(3):259-60; author reply 259-60. PubMed ID: 12529472
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics of peginterferons.
    Zeuzem S; Welsch C; Herrmann E
    Semin Liver Dis; 2003; 23 Suppl 1():23-8. PubMed ID: 12934165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C.
    Ferenci P
    Int J Clin Pract; 2003 Sep; 57(7):610-5. PubMed ID: 14529063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.